89bio, Inc. (ETNB) financial statements (2022 and earlier)

Company profile

Business Address 535 MISSION STREET
SAN FRANCISCO, CA 94105
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:150,700204,60093,335
Cash and cash equivalents52,43298,18393,335
Short-term investments 106,446 
Other undisclosed cash, cash equivalents, and short-term investments98,268(29) 
Restricted cash and investments252525
Prepaid expense3,342  
Other undisclosed current assets7,9155,5771,966
Total current assets:161,982210,20295,326
Noncurrent Assets
Property, plant and equipment150166155
Other noncurrent assets29070672
Total noncurrent assets:440872227
TOTAL ASSETS:162,422211,07495,553
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities17,0378,1135,609
Accounts payable6,8432,065989
Accrued liabilities10,1946,0484,620
Debt2,500  
Total current liabilities:19,5378,1135,609
Noncurrent Liabilities
Long-term debt and lease obligation16,898  
Long-term debt, excluding current maturities16,898  
Other undisclosed noncurrent liabilities30  
Total noncurrent liabilities:16,928  
Total liabilities:36,4658,1135,609
Stockholders' equity
Stockholders' equity attributable to parent125,957202,96189,944
Common stock202014
Additional paid in capital339,218326,046163,526
Accumulated other comprehensive loss(64)(10) 
Accumulated deficit(213,217)(123,095)(73,596)
Total stockholders' equity:125,957202,96189,944
TOTAL LIABILITIES AND EQUITY:162,422211,07495,553

Income statement (P&L) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
Operating expenses(89,743)(49,355)(26,640)
Operating loss:(89,743)(49,355)(26,640)
Nonoperating expense
(Other Nonoperating expense)
(526)(203)(30,562)
Interest and debt expense (230) 
Loss from continuing operations before equity method investments, income taxes:(90,269)(49,788)(57,202)
Other undisclosed income from continuing operations before income taxes 230 
Loss from continuing operations before income taxes:(90,269)(49,558)(57,202)
Income tax expense (benefit)14759(218)
Net loss available to common stockholders, diluted:(90,122)(49,499)(57,420)

Comprehensive Income ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
Net loss:(90,122)(49,499)(57,420)
Other comprehensive loss(54)(10) 
Comprehensive loss, net of tax, attributable to parent:(90,176)(49,509)(57,420)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: